CDT Equity's AZD5904 Advances to Patent Cooperation Treaty Phase
CDT Equity (CDT) announced that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca (AZN), has progressed into the patent cooperation treaty phase. A total of 181 subjects were dosed across five Phase 1 studies. The asset has demonstrated a favorable safety profile, with no overtly drug-related adverse events identified. The company believes this level of human clinical validation, alongside its IP position. The company holds both a composition of matter patent and a method of use patent relating to AZD5904 in idiopathic male infertility, supported by pre-clinical data demonstrating its potential. The progression to PCT stage enables CDT to pursue broader international protection, supporting the potential global development and commercialization of the asset. The company said CDT has identified promising signals for AZD5904 in idiopathic male infertility, as well as in related oncology-associated infertility markets. The company believes these indications represent areas of significant unmet medical need and commercial opportunity. CDT is now actively seeking out-licensing and strategic partnering opportunities to advance AZD5904 into later-stage development.
